VA-FLUENCE
Fluence , a Siemens and AES company, today unveiled its sixth-generation energy storage technology stack combining factory-built hardware, advanced software and data-driven intelligence. Drawing on more than 12 years of industry leadership and innovation, the new technology is changing the way energy storage systems are built and operated — making them simpler, safer, faster and more cost-effective to deploy at scale.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200616005326/en/
The technology stack creates the foundation for three purpose-built systems, GridstackTM , SunstackTM and EdgestackTM , that are configured for grid, renewable and commercial & industrial (C&I) applications, respectively, while easily addressing the need for larger systems and larger fleets of systems. Fluence has already been selected by leading customers such as Enel, LS Power, sPower and Siemens for 800 megawatts, 2300 megawatt-hours, of projects using the new technology.
“Energy storage applications require highly flexible systems that can be tailored to specific markets and customer needs,” said Fluence CTO Brett Galura. “Until now, customers were forced to choose between custom-built solutions or inflexible, vertically integrated products. This sixth-generation technology combines our proprietary dataset – among the industry’s largest – and our deep industry experience to deliver unparalleled intelligence and flexibility, while adding the benefits of mass production to standardize safety features and significantly reduce the time and cost needed to deploy energy storage. Over the past decade, Fluence has reduced the total cost of energy storage systems by 90 percent; our new technology stack focuses on driving down the non-battery costs of energy storage systems by up to 25 percent, while empowering gigawatt-sized deployments.”
Fluence’s new technology stack includes three components:
- Fluence IQ : Digital intelligence engines use data and machine learning to improve system decision-making, manage battery degradation, reduce operating costs and optimize energy market dispatch.
- Fluence Operating System (OS) : Built on a decade of digital control system development, the fully integrated operating platform combines comprehensive controls, system visibility and asset management to improve asset performance at a single site or across entire fleets.
- Fluence Cube : The factory-assembled building block is 4-5x more modular than traditional systems and incorporates the latest technologies for rapid installation and scale, consistent operations & maintenance and improved quality control.
Fluence Cube, OS and IQ incorporate enhanced safety features to meet the most stringent safety standards, such as NFPA 855 and UL 9540A. Together, they provide the foundation for three pre-configured energy storage systems optimized for specific market segments and project needs:
- Gridstack : A utility-scale system designed for the most demanding grid applications (such as T&D enhancement, frequency regulation and capacity peak power), with industry-leading reliability and safety.
- Sunstack: A PV-optimized, co-located system designed to improve and expand the capabilities of solar generation with firm renewable energy delivery and additional grid services.
- Edgestack : A commercial & industrial system designed to support 500+ kW applications with rapid deployment and minimum footprint to reduce demand charges and provide critical power.
Major global power suppliers and industrial customers have already committed to deploy Fluence’s sixth-generation technology in Asia Pacific, North America and Europe. Siemens is delivering Gridstack and Edgestack for customers in Germany, Portugal and Finland.
“Battery storage is a rapidly growing segment and crucial for the energy transition. For the cost-efficient and fast execution of projects in the area of distributed energy, microgrids and eMobility infrastructure, the productization and modularization of storage technologies are decisive. With the new stack & OS approach, Fluence has a unique system providing cutting-edge safety,” said Jean-Christoph Heyne, Global Head of Future Grids, Siemens AG.
“Cost-competitive technologies, aggressive emissions targets and increased need for grid reliability and resilience are driving global utility and C&I demand for energy storage, which BloombergNEF predicts will attract more than $560 billion in investment by 2040,” said Fluence CEO Manuel Perez Dubuc. “What separates our carbon-intensive past from a sustainable future is market inflection. With the introduction of our next-generation design, Fluence is helping drive that inflection, making it more cost-effective, faster and safer to replace smokestacks with tech stacks that provide communities around the world with cleaner, more resilient energy systems.”
About Fluence
Fluence, a Siemens and AES company, is the global market leader in energy storage technology solutions and services, combining the agility of a technology company with the expertise, vision and financial backing of two well-established and respected industry giants. Building on the pioneering work of AES Energy Storage and Siemens energy storage, the company’s goal is to create a more sustainable future by transforming the way we power our world. Providing design, delivery and integration, Fluence offers proven energy storage technology solutions that address the diverse needs and challenges of customers in a rapidly transforming energy landscape. The company currently has more than 2.1 gigawatts of projects in operation or awarded across 22 countries and territories worldwide. Fluence topped the Navigant Research utility-scale energy storage leaderboard in 2018 and was named one of Fast Company’s Most Innovative Companies in 2019.
To learn more about Fluence, please visit: fluenceenergy.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200616005326/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Curing the Incurable with ‘Biological Age Zero’ Cells: Clonell™ Launches the Ultimate Regenerative Medicine Platform5.1.2026 14:00:00 CET | Press release
Fundamental Cure for Intractable and Incurable Diseases using ‘Biological Age Zero’ Cells Derived from Patient’s Own Cells via SCNT TechnologyWorld's First Therapy Platform Simultaneously Solving Immune Rejection and Inheritance of Cellular Aging—The Major Hurdles of Existing Stem Cell TherapiesDrastically Improving Treatment Accessibility through the New Paradigm, ‘Patient-Initiated Clinical Trial™’, which Overcomes Existing Clinical Limitations Clonell Therapeutics, Inc., a leading biotechnology company dedicated to curing intractable and incurable diseases, announced today the official launch of the world's first 'Patient-Specific Embryonic Stem Cell (Somatic Cell Nuclear Transfer-derived Embryonic Stem Cell, hereinafter SCNT-ESC)' therapy platform based on Somatic Cell Nuclear Transfer (SCNT) technology. Concurrently, the company has initiated its innovative 'Patient-Initiated Clinical Trial™' to apply this breakthrough technology directly to patients. This platform launch is evalu
HELUS Pharma Propels Therapeutic Innovation in Mental Health and Commences Trading on Nasdaq5.1.2026 13:30:00 CET | Press release
Helus Pharma builds on the strong foundation originally created as Cybin Inc., reflecting the Company’s ongoing transformation to a commercial stage pharmaceutical company Helus Pharma commences trading on Nasdaq Global Market (“Nasdaq”) and on Cboe Canada under ticker symbol: HELP Helus Pharma continues to progress its portfolio of novel serotonergic agonists (“NSAs”), with the goal of developing treatments designed to redefine mental health care, including HLP004 for the treatment of generalized anxiety disorder, with Phase 2 topline data readout expected in Q1 2026 Preparations in progress for the commercialization of HLP003, Helus Pharma’s NSA in Phase 3 clinical development, which has been granted Breakthrough Therapy Designation by the FDA for the adjunctive treatment of major depressive disorder This news release constitutes a “designated news release” for the purpose of the Company’s prospectus supplement dated December 30, 2025, to it short form base shelf prospectus dated Sep
Incyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi®/Minjuvi®) as a First-line Treatment for Diffuse Large B-Cell Lymphoma5.1.2026 13:30:00 CET | Press release
- Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP met its primary endpoint of progression-free survival (PFS) - Based on these results, Incyte plans to file a supplemental Biologics License Application (sBLA) for tafasitamab and lenalidomide in addition to R-CHOP in first-line diffuse large B-cell lymphoma (DLBCL) in the first half of 2026 Incyte (Nasdaq:INCY) today announced positive topline results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, and lenalidomide in addition to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone) compared to R-CHOP alone as a first-line treatment for adults with newly diagnosed diffuse large B-cell lymphoma (DLBCL) with an International Prognostic Index (IPI) score of three to five (3-5) for patients >60 years o
SBC Medical Accelerates Global Expansion with Strategic Investment and Alliance witha Leading U.S. MedSpa Platform OrangeTwist as Part of Broader Growth Strategy5.1.2026 13:00:00 CET | Press release
SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a global provider of comprehensive consulting and management services to medical corporations and their clinics, today announced the completion of a strategic minority equity investment and the establishment of a structured collaboration framework with OrangeTwist, a leading U.S.-based MedSpa chain, alongside its longstanding institutional shareholders, Hildred Capital and Athyrium Capital. This transaction marks SBC Medical’s formal entry into the United States—a key global market for medical aesthetics—and represents a major milestone in the Company’s broader global expansion strategy. For more details, click here. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251210926005/en/ OrangeTwist Supporting 258 affiliated clinics worldwide and managing more than six million patient visits annually, SBC Medical has built one of the largest and
Takeda and Protagonist Announce Submission of New Drug Application (NDA) for Rusfertide for Treatment of Polycythemia Vera (PV)5.1.2026 13:00:00 CET | Press release
Rusfertide Is a First-in-Class Investigational Hepcidin Mimetic That Targets Red Blood Cell Overproduction (Erythrocytosis) in Polycythemia Vera NDA Includes 52-Week Data from Phase 3 VERIFY Study, Which Met the Primary and All Four Key Secondary Endpoints, Showing Rusfertide Provided Durable and Sustained Hematocrit Control and Improved Pre-Specified Patient Reported Outcome Measures Data Underscore the Potential to Shift the Treatment Paradigm for PV Patients to Reduce the Burden of Frequent Phlebotomies and Meaningfully Improve Hematocrit Control Takeda (TSE:4502/NYSE:TAK) and Protagonist Therapeutics (Nasdaq: PTGX) (“Protagonist”) announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval of rusfertide for the treatment of adults with polycythemia vera (PV). Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell product
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
